Figure 1
Expression of miR-100 in AML patients and the human leukemia cell line HL60 following induction with all-trans retinoic acid (ATRA) and 1α, 2,5-dihydroxyvitamin D3 (1,25D3). (a, b) The expression level of mature miR-100 (a) and miR-100 precursor (b) in AML patients (from AML M1 to M5), respectively, was quantified by real-time PCR, normalized to the expression of U6 and presented as the 2−ΔΔCt value relative to the normal samples. Both mature miR-100 and miR-100 precursor was significantly upregulated in the M1, M2 and M3 subtypes in comparison with the healthy controls, but a low expression level was detected in the M4, M5 subtypes (**P<0.01). (c, d) MiR-100 expression was detected in HL60 cells after 48 h and 96 h of treatment with different concentrations of ATRA (c) and 1,25D3 (d) by qRT–PCR, respectively. (e, f) A time-dependent downregulation of miR-100 in HL60 cells was observed following exposure to 1 μM ATRA (e) and 100 nM 1,25D3 (f). The asterisks demonstrate statistically significant differences compared with the corresponding vehicle-treated control (CTL) (*P<0.05). (g) MiR-100 precursor expression was determined at 12 h and 96 h after treatment of 1 μM ATRA or 100 nM 1,25D3, respectively, by Northern blot. The value under each sample indicates the fold change of miR-100 precursor level in ATRA- or 1,25D3-treated cells, relative to that in CTL. A full colour version of this figure is available at the Oncogene journal online.
